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A 30-year-old AIIX patient, with a CD4 count of 
30 cells/nini3, presented with a three-month history 
of involuntary weight loss, anorexia, night sweats and 
abdominal disconifort, particularly in the right iliac 
fossa. He also complained of watery brown diarrhoea, 
LIP to eight times per day. Current medication iiicluded 
triple combination antiretroviral therapy, although 
compliance was questionable. He had had an episode 
of Pner~rnocysris caririii pneumonia 13-months pre- 
viously. Family history was unremarkable. Exaiiiiriation 
revealed a pale. thin man, w h o  was tender i n  his  right 
iliac fossa, where he had an ill-defined tiiacs. He 
also had Jiepstosplenoniegaly, but no palpable lymph 
nodes. Labordtory tests showed the haemoglobin was 
8.2 g/dl (normal range 13.0-17.0 g/dl), i n e m  cell 
volume 91 fl (NR 80-100 fl), white blood cells 3.9 x 
10" (NK 4.0-11.0 x 10"). pldtelets 119 x 10'' ( N R  
150-100 x 10") and C Keactive Protein 21 0 mg/L 
(NR < 7  0 mg/L). Urea  and electrohte5 were noriiial, 
a G T  445 IU/L (NR 8-78 IU/L), alkaline phosphatase 
371 IU/L (NR 38-1 26 IU/L), alanine tiansaniinase 
46 IU/L (NK <55 IU/L), bilirubin 8 p o l / L  (NR 
<22 pinol/L) Stool sanlples on several occasion5 had 
been pathogen nept ive 
Questions 
1. What abnormalities are evident in the gross patho- 
2. What further investigations are indicated 
3. What  is the most likely diagnosis 
4, What 1s the treatment and prognosiv 
logical specimen 
Answers 
1. Multiple polyps In the caecum m d  axending colon 
2 Double contrast barium enenid with wb\equent 
fibreoptic colonoscopv and blopn 
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3.  High grade B-cell lymphoma 
1. Recent studies favour a low dose regime of multi- 
agent chemotherapy (e.g. ml3ACOD - metho- 
trexate, bleomycin, doxorubicin, cyclophosphamide, 
vincristine and dexamethasone) along with CNS 
prophylaxis and antiretroviral treatment. This 
approach has resulted in complete remission rates of 
up to 65%, with intercurrent opportunistic infect- 
ions in only 8%, decreased bone marrow suppression 
and a median survival of approximately 18 months 
in responders. 
In 1985 lymphoma was designated as an AIDS-defining 
condition. In patients with HIV the risk of lymphoma 
is increased 60 to 100-fold and has a predilection 
for extranodal sites (60-98%). It is usually a late 
manifestation of HIV infection, and with increasingly 
prolonged survival, larger numbers of patients with 
lymphoma are expected. It affects the different trans- 
mission categories equally (drug users, haemophiliacs, 
homosexuals, heterosexuals and blood product recipients) 
and also those from different geographical locations. 
After the CNS, the gastrointestinal tract is the second 
most commonly affected site, with typical symptoms 
and signs including change in bowel habits, gross 
or occult blood per rectum, involuntary weight 
loss, abdominal pain, abdominal tenderness, peripheral 
lymphadenopathy, cachexia, and hepatosplenomegaly. 
Factors associated with shorter survival include history 
of AIDS prior to the lymphoma, low CD4 cells (less 
than 200/mm3), Karnofsky performance status less than 
70%, stage IV disease and bone marrow involvement. 
Systemic ‘B’ symptoms (weight loss, unexplained fever 
and/or night sweats) are seen in 80-90% of patients at 
diagnosis, however do not obviate the need for a careful 
search for occult opportunistic infection that may be 
amenable to treatment. 
There is no consensus on what constitutes an ideal 
treatment regime. Current strategies attempt to com- 
bine an ti-retroviral medication, meningeal prophylaxis 
and infection prophylaxis into chemotherapy protocols. 
A systemic approach is essential considering that truly 
localised disease is exceptional. Patients need stratifying 
into good and poor prognostic groups, with the former 
being able to tolerate the more intensive regimes. Due 
to bone marrow suppression some antiretroviral agents, 
such as zidovudine (AZT), are contraindicated, how- 
ever others, such as dideoxycytosine (ddC), may be 
associated with increased regime efficacy. 
This case illustrates the value of post mortem 
examination in advancing our knowledge of the natural 
history of HIV/AIDS and its secondary manifestations. 
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